The iPrEx study shows that individuals at high risk of HIV infection who took two widely used HIV medications, emtricitabine and tenofovir experienced an average of 43.8% fewer HIV infections than those who received a placebo pill. 2,499 individuals at high risk of HIV infection participated in the study in six countries. The results of the study were reported in the New England Journal of Medicine and iPrEx was listed in Time magazine as one of the top ten medical breakthroughs for 2010. Dr. Robert Grant is the Protocol Chair for the iPrEx study.
